Heads roll as JNJ seeks to strengthen ailing medtech biz
This article was originally published in Clinica
Executive Summary
Johnson & Johnson may have led the medtech industry for many years, but its increasingly weakening hold of the top position was confirmed today, following news that the healthcare giant was cutting around 3,000 jobs in its orthopedics, surgery and cardiovascular businesses to reduce costs and hopefully turn the division around.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.